Chronic endothelin receptor blockade reduces end-organ damage independently of blood pressure effects in salt-loaded heterozygous Ren-2 transgenic rats

Physiological Research

Volumn 53, Issue 6, 2004, Pages 581-593

  Opocensky M ^a   Dvorak P ^a   Maly J ^a   Kramer, H J ^b   Backer A ^b   Kopkan, L ^a   Vernerova Z ^a   Tesar V ^a   Zima, T ^a   Bader, M ^c   Ganten, D ^c   Janda, J ^a   Vaneckova I ^a,d  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY OF BONN   (Germany)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^d INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

Bosentan; End organ damage; Endothelin system; Hypertension; Renin angiotensin system

Indexed keywords

BOSENTAN; ENDOTHELIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DRUG EFFECT; GENE; GLOMERULOSCLEROSIS; HETEROZYGOSITY; MALE; NONHUMAN; ORGAN INJURY; PHASE TRANSITION; PLETHYSMOGRAPHY; RAT; RECEPTOR BLOCKING; REN2 GENE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SALT LOADING; SURVIVAL RATE; TRANSGENIC ANIMAL;

ADMINISTRATION, ORAL; ANIMALS; ANIMALS, GENETICALLY MODIFIED; BLOOD PRESSURE; FEMALE; HYPERTENSION; MALE; MULTIPLE ORGAN FAILURE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ENDOTHELIN; RENIN; RENIN-ANGIOTENSIN SYSTEM; SEVERITY OF ILLNESS INDEX; SODIUM CHLORIDE; SULFONAMIDES; SURVIVAL RATE;

EID: 19944425935     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. ALEXANDER RW: Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension 25: 495-500, 1995.
2. ALEXANDER BT, COCKRELL KL, RINEWALT AN, HERRINGTON JN, GRANGER JP: Enhanced renal expression of preproendothelin mRNA during chronic angiotensin II hypertension. Am J Physiol 280: R1388-R1392, 2001.
3. ANDREIS PG, REBUFFAT P, NERI G, ROSSI GP, NUSSDORFER GG: Effects of irbesartan and bosentan on the blood pressure and adrenal zona glomerulosa function in heterozygous transgenic TGR(mRen2)27 rats. Life Sci 67: 543-547, 2000.
4. BÄCKER A, BOKEMEYER D, KRAMER HJ: Endothelin synthesis and receptors in porcine kidney. Acta Physiol Scand 171: 105-112, 2001.
5. BALTATU O, CAYLA C, ILIESCU R, ANDREEY D, JORDAN C, BADER M. Abolition of hypertension-induced end-organ damage by androgen receptor blockade in transgenic rats harboring the mouse Ren-2 gene. J Am Soc Nephrol 13: 2681-2687, 2002.
6. BREU VB, LÖFLER BM, GANTEN D, SCHNEIDER W, HALLER H, LUFT FC: Effect of bosentan on NF-κB, inflammation, and tissue factor in angiotensin II-induced end-organ damage. Hypertension 36: 282-290, 2000.
7. CALLAHAN MF, LI P, FERRARIO CM, GANTEN D, MORRIS: Salt-sensitive hypertension in (mREN-2)27 transgenic rats. Hypertension 27: 573-577, 1996.
8. CARGNELLI G, ROSSI GP, PESSINA AC, LUCIANI S, DEBETTO P, GANTEN D, PETERS J, BOVA S: Changes of blood and aortic strip contractile response to ET-1 of heterozygous female transgenic rats, TGR(mRen2)27. Pharmacol Res 37: 207-211, 1998.
9. CHUANG O, SCHIPS T, ROHMEISS P, GRETZ N, STRAUCH M, UNGER T: Protein excretion and renal adaptation of transgenic mRen2 rats to changing oral sodium loads. J Hypertens 11 (Suppl 5): S188-S189, 1993.
10. DE NUCCI G, GRYGLEWSKI RJ, WARNER TD, VANE JR: Receptor-mediated release of endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled. Proc Natl Acad Sci USA 85: 2334-2338, 1998.
11. DOBEŠOVÁ Z, KUNEŠ J, ZICHA J: Less important role of endothelin in salt hypertension of young than adult Dahl rats. Physiol Res 52: 49P, 2003.
12. A-receptor blockade in angiotensin II-induced hypertension. Hypertension 29: 435-441, 1997.
13. DVOŘÁK P, KOPKAN L, ČERVENKA L: Effects of bosentan on the malignant phase of hypertension in hypertensive Ren-2 transgenic rats. Physiol Res 51: 66P, 2002a.
14. DVOŘÁK P, KOPKAN L, ČERVENKA L: The role of endothelin-1 in the development of salt-sensitive hypertension and end-organ damage in heterozygous hypertensive Ren-2 transgenic rats. Physiol Res 51: 66P, 2002b.
15. A receptor blockade attenuates cardiac hypertrophy independently of blood pressure effects in renovascular hypertensive rats. Hypertension 33: 954-960, 1999.
16. FICAI S, HERIZI A, MIMRAN A, JOVER B: Endothelin blockade in angiotensin II hypertension: prevention and treatment studies in the rat. Clin Exp Pharmacol Physiol 28: 1100-1103, 2001.
17. GARDINER SM, MARCH JE, KEMP PA, MULLINS JJ, BENETT T: Haemodynamic effects of losartan and the endothelin antagonist, SB 209670, in conscious, transgenic (mRen-2)27, hypertensive rats. Br J Pharmacol 116: 2237-2244, 1995.
18. GARDINER SM, MARCH JE, KEMP PA, BENNET T: Cardiovascular effects of endothelin-1 and endothelin antagonists in conscious, hypertensive (mRen-2)27 rats. Br J Pharmacol 131: 1732-1738, 2000.
19. GUIJARRO C, EGIDO J: Transcription factor-κB (NF-κB) and renal disease. Kidney Int 59: 415-424, 2001.
20. HELLER J, HELLEROVÁ S: Long-term effect on blood pressure of early brief treatment by different antihypertensive agents: a study in the Prague hypertensive rat. Kidney Blood Press Res 21: 445-451, 1998.
21. HILGERS KF, PETERS J, VEELKEN R. SOMMER M, RUPPRECTH G, GANTEN D, LUFT FC, MANN JF: Increased vascular angiotensin formation in female rats harboring the mouse Ren-2 gene. Hypertension 19: 687-691, 1992.
22. HOECHER B, THONE-REINEKE C, ROHMEISS P, SCHMAGER F, SLOWINSKI T, BURST V, SIEGMUND F, QUERTERMOUS T, BAUER C, NEUMAYER HH, SLEUNING WD, THEURING F: Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest 99: 1380-1389, 1997.
23. JACINTO SM, MULLINS JJ, MITCHELL KD: Enhanced renal vascular responsiveness to angiotensin II in hypertensive ren-2 transgenic rats. Am J Physiol 276: F315-F322, 1999.
24. KELLY DJ, SKINNER SL, GILBERT RE, COX AJ, COOPER ME, WILINSON-BERKA JL: Effects of endothelin or angiotensin II receptor blockade on diabetes in the transgenic (mRen-2)27 rat. Kidney Int 57: 1882-1894, 2000.
25. LANGHEINRICH M, LEE MA, BÖHM M, PINTO YM, GANTEN D, PAUL M: The hypertensive Ren-2 transgenic rat TGR(mRen2)27 in hypertension research. Characteristics and functional aspects. Am J Hypertens 9: 506-512, 1996.
26. LEE MA, BÖHM M, PAUL M, BADER M, GANTEN U, GANTEN D: Physiological characterization of the hypertensive transgenic rat TGR(mRen2)27. Am J Physiol 270: E919-E929, 1996.
27. LI L, CHU Y, FINK GD, ENGELHARDT JF, HEISTAD DD, CHEN AF: Endothelin-1 stimulates arterial VCAM-1 expression via NADPH oxidase-derived superoxide in mineralocorticoid hypertension. Hypertension 42: 997-1003, 2003.
28. LUFT FC: Endothelin, nephropathy, and blood pressure. J Mol Med 80: 69-70, 2002.
29. MOREAU P, SCHIFFRIN EL: Role of endothelin in animal models of hypertension: focus on cardiovascular protection. Can J Physiol Pharmacol 81: 511-521, 2003.
30. MÜLLER DN, MERVAALA EMA, SCHMIDT F, PARK JK, DECHEND R, GENERSCH E, LÖFFLER BM, GANTEN D, SCHNEIDER W, HALLER H. LUFT FC: Effect of bosentan on NF-κB, inflammation, and tissue factor in angiotensin II-induced end-organ damage. Hypertension 36: 282-290, 2000.
31. MÜLLER DN, MULLALLY A, DECHEND R, PARK JK, FIEBERLER A, PILZ B, LÖFFLER BM, BLUM-KAELIN D, MASUR S, DEHMLOW H, JOHANNES D, HALLER H, LUFT FC: Endothelin-converting enzyme inhibition ameliorates angiotensin II-induced cardiac damage. Hypertension 40: 840-846, 2002.
32. MULLINS J, PETERS J, GANTEN D: Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature 344: 541-544, 1990.
33. NUSSDORFER GG, ROSSI GP, MALENDOWICZ LK, MAZOCCHI G: Autocrine-paracrine endothelin system in the physiology and pathology of steroid-secreting tissues. Pharmacol Rev 51: 403-438, 1999.
34. A-receptor blocker (LU 135252) in salt-loaded uninephrectomized stroke-prone spontaneously hypertensive rats. Hypertension 31: 995-1001, 1998.
35. PARK JB, SCHIFFRIN EL: Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats: role of endothelin-1. Am J Hypertens 15: 164-169, 2002.
36. PETERS J, MÜNSTER K, BADER M, HACKENHAL E, MULLINS JJ, GANTEN D: Increased adrenal renin in transgenic hypertensive rats, TGR(mREN)27, and its regulation by cAMP, angiotensin II and calcium. J Clin Invest 91: 742-747, 1993.
37. PU Q, NEVES MF, VIRDIS A, TOUYZ RM, SCHIFFRIN EL: Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension 42: 49-55, 2003.
38. B activation in vivo and modulation by receptor antagonism. Am J Physiol 274: R131-R138, 1998.
39. RECKELHOFF JF: Gender differences in the regulation of blood pressure. Hypertension 37: 1199-1208, 2001.
40. RECKELHOFF JF, ROMERO CJ: Role of oxidative stress in angiotensin-induced hypertension. Am J Physiol 284: R893-R912, 2003.
41. ROSSI GP, SACCHETTO A, RIZZONI D, BOVA S, PORTERI E, MAZZOCCHI G, BELLONI AS, BAHCELIOGLU M, NUSSDORFER GG, PESSINA AC: Blockade of angiotensin II type 1 receptor and not of endothelin receptor prevents hypertension and cardiovascular disease in transgenic (mRen2)27 rats via adrenocortical steroid-independent mechanisms. Arterioscler Thromb Vasc Biol 20: 949-956, 2000.
42. B receptor imbalance differentiates salt-sensitive from salt-resistant spontaneous hypertension. Hypertension 37: 275-280, 2001.
43. ROTHERMUND L, KOSSMEHL P, NEUMAYER HH, PAUL M, KREUTZ R: Renal damage is not improved by blockade of endothelin receptors in primary renin-dependent hypertension. J Hypertens 21: 2389-2397, 2003.
44. SAAM T, EHMKE H, HAAS C, RITZ E, AMANN K: Effect of endothelin blockade on early cardiovascular remodeling in the one-clip, two-kidney hypertension of the rat. Kidney Blood Press Res 26: 325-332, 2003.
45. SASSER JM, POLLOCK JS, POLLOCK DM: Renal endothelin in chronic angiotensin II hypertension. Am J Physiol 283: R243-R248, 2002.
46. SECCIA TM, BELLONI AS, KREUTZ R, PAUL M, NUSSDORFER GG, PESSINA AC, ROSSI GP: Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II. J Am Coll Cardiol 41: 666-673, 2003.
47. SHINDO T, KURIHARA H, MAEMURA K, KURIHARA Y, UEDA O, SUZUKI H, KUWAKI T, JU K, WANG Y, EBIHARA A, NISHIMATSU H, MORIYAMA N, FUKUDA M, AKIMOMOTO Y, HIRANO H, MORITA H, KUMADA M, YAZAKI Y, NAGAI R, KIMURA K: Renal damage and salt dependent hypertension in aged transgenic mice overexpressing endothelin-1. J Mol Med 80: 105-116, 2002.
48. B receptor-deficient rats. Effects of a high salt diet. Hypertension 41: 657-662, 2003.
49. YAGIL C, SAPOJNIKOV M, KATNI G, ILAN Z, ZANGEN SW, ROSENMANN E, YAGIL Y: Proteinuria and glomerulosclerosis in the Sabra genetic model of salt susceptibility. Physiol Genomics 9: 167-178, 2002.
50. B receptors in the renal medulla. Hypertension 41: 1359-1363, 2003.
51. WHITHWORTH CE, VENIANT MM, FIRTH JD, CUMMING AD, MULLINS JJ: Endothelin in the kidney in malignant phase hypertension. Hypertension 26: 925-931, 1995.
52. ZICHA J, KUNEŠ J: Ontogenetic aspects of hypertension development: analysis in the rat. Physiol Rev 79: 1227-1282, 1999.